Volume 23 Issue 11
Nov.  2025
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2025  >  23(11): 1862-1865
WANG Lili, ZHAO Yunqi, WANG Xin, XIE Changhao. Analysis of clinical characteristics and risk factors in primary antiphospholipid syndrome with thrombocytopenia[J]. Chinese Journal of General Practice, 2025, 23(11): 1862-1865. doi: 10.16766/j.cnki.issn.1674-4152.004246
Citation: WANG Lili, ZHAO Yunqi, WANG Xin, XIE Changhao. Analysis of clinical characteristics and risk factors in primary antiphospholipid syndrome with thrombocytopenia[J]. Chinese Journal of General Practice, 2025, 23(11): 1862-1865. doi: 10.16766/j.cnki.issn.1674-4152.004246
shu

Analysis of clinical characteristics and risk factors in primary antiphospholipid syndrome with thrombocytopenia

doi: 10.16766/j.cnki.issn.1674-4152.004246

  • Department of Rheumatology and Immunology, the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

Funds:

 2108085MH258

  • Received Date: 2024-11-29
    Available Online: 2026-01-07
    Abstract
  •   Objective  To understand the main clinical characteristics of primary antiphospholipid syndrome (APS) complicated with thrombocytopenia and explore the risk factors for thrombocytopenia in APS.  Methods  A retrospective analysis was conducted on 69 APS patients who were enrolled from the First Affiliated Hospital of Bengbu Medical University from January 2016 to February 2024. Clinical data and laboratory test results were collected, and patients with platelet count (PLT) < 100×109/L were defined as cases of thrombocytopenia, and were divided into two groups: the observation group (n=16) with APS complicated thrombocytopenia and the control group (n=53) with normal platelet count clinical manifestations, laboratory tests, and immunological indicators were compared between the two groups. A multiple logistic stepwise regression model was used to analyze the risk factors for thrombocytopenia in APS patients.  Results  Out of 69 APS patients, a total of 16 (23.2%) developed thrombocytopenia. No statistically significant difference was observed between the observation and control groups in terms of clinical characteristics, including thrombosis, heart valve disease, neurological disorders, and renal disorders (P>0.05). The incidence of hypocomplementemia in the observation group was significantly higher than that in the control group [75.0% (12/16) vs. 43.4% (23/53), P < 0.05]. Compared with the control group, the incidence of abnormal decrease in fibrinogen in the observation group was also significantly higher [43.8% (7/16) vs. 15.1% (8/53), P < 0.05]. In addition, there was no statistically significant difference in the positive rate of autoantibodies between the two groups. Multivariate analysis showed that hypocomplementemia (OR=0.198, P < 0.05) and decreased Fib (OR=0.216, P < 0.05) were both independent risk factors for thrombocytopenia complicated with APS.  Conclusion  Thrombocytopenia is common in APS patients, with low complement levels and decreased fibrinogen being independent risk factors for APS complicated with thrombocytopenia.

     

    • FullText(HTML)
  • loading
    • References(22)
  • [1]
    MIYAKIS S, LOCKSHIN M D, ATSUMI T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)[J]. J Thromb Haemost, 2006, 4(2): 295-306. doi: 10.1111/j.1538-7836.2006.01753.x
    [2]
    白伊娜, 孟菁菁, 赵久良, 等. 抗磷脂综合征中非标准抗磷脂抗体的诊断价值和风险预测[J]. 中华临床免疫和变态反应杂志, 2023, 17(5): 395-406.

    BAI Y N, MENG J J, ZHAO J L, et al. Diagnostic value and risk prediction of non-criteria antiphospholipid antibodies in antiphospholipid syndrome[J]. Chinese Journal of Allergy & Clinical Immunology, 2023, 17(5): 395-406.
    [3]
    PARDOS-GEA J, MARQUES-SOARES J R, BUJÁN S, et al. Persistent thrombocytopenia predicts poor long-term survival in patients with antiphospholipid syndrome: a 38-year follow-up study[J]. Rheumatology(Oxford), 2022, 61(3): 1053-1061. doi: 10.1093/rheumatology/keab475
    [4]
    NEUNERT C, LIM W, CROWTHER M, et al. The American society of hematology 2011 evidence-based practice guideline for immune thrombocytopenia[J]. Blood, 2011, 117(16): 4190-4207. doi: 10.1182/blood-2010-08-302984
    [5]
    MITITELU A, ONISÂI M C, ROŞCA A, et al. Current understanding of immune thrombocytopenia: a review of pathogenesis and treatment options[J]. Int J Mol Sci, 2024, 25(4): 2163. DOI: 10.3390/ijms25042163.
    [6]
    PATSOURAS M, TSIKI E, KARAGIANNI P, et al. The role of thrombospondin-1 in the pathogenesis of antiphospholipid syndrome[J]. J Autoimmun, 2020, 115: 102527. DOI: 10.1016/j.jaut.2020.102527.
    [7]
    TANG Z, SHI H, CHEN C, et al. Activation of platelet mTORC2/Akt pathway by anti-β2GP1 antibody promotes thrombosis in antiphospholipid syndrome[J]. Arterioscler Thromb Vasc Biol, 2023, 43(10): 1818-1832. doi: 10.1161/ATVBAHA.123.318978
    [8]
    TOHIDI-ESFAHANI I, MITTAL P, ISENBERG D, et al. Platelets and thrombotic antiphospholipid syndrome[J]. J Clin Med, 2024, 13(3): 741. DOI: 10.3390/jcm13030741.
    [9]
    CERVERA R, TEKTONIDOU M G, ESPINOSA G, et al. Task force on catastrophic antiphospholipid syndrome (APS) and non-criteria APS manifestations (Ⅱ): thrombocytopenia and skin manifestations[J]. Lupus, 2011, 20(2): 174-181. doi: 10.1177/0961203310395052
    [10]
    YELNIK C M, NGUYEN Y, LE GUERN V, et al. Thrombocytopenia in primary antiphospholipid syndrome, a marker of high-risk patients?[J]. Eur J Intern Med, 2020, 74: 106-107. doi: 10.1016/j.ejim.2020.01.017
    [11]
    BARBHAIYA M, ZUILY S, NADEN R, et al. The 2023 ACR/EULAR antiphospholipid syndrome classification criteria[J]. Arthritis Rheumatol, 2023, 75(10): 1687-1702. doi: 10.1002/art.42624
    [12]
    KRAUSE I, BLANK M, FRASER A, et al. The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome[J]. Immunobiology, 2005, 210(10): 749-754. doi: 10.1016/j.imbio.2005.10.005
    [13]
    DEMETRIO PABLO R, MUÑOZ P, LÓPEZ-HOYOS M, et al. Thrombocytopenia as a thrombotic risk factor in patients with antiphospholipid antibodies without disease criteria[J]. Med Clin(Barc), 2017, 148(9): 394-400.
    [14]
    SHI Y, ZHAO J, JIANG H, et al. Thrombocytopenia in primary antiphospholipid syndrome: association with prognosis and clinical implications[J]. Rheumatology(Oxford), 2022, 62(1): 256-263. doi: 10.1093/rheumatology/keac264
    [15]
    PABLO R D, CACHO P M, LÓPEZ-HOYOS M, et al. Risk factors for the development of the disease in antiphospholipid antibodies carriers: a long-term follow-up study[J]. Clin Rev Allergy Immunol, 2022, 62(2): 354-362. doi: 10.1007/s12016-021-08862-5
    [16]
    PROULLE V, FURIE R A, MERRILL-SKOLOFF G, et al. Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS[J]. Blood, 2014, 124(4): 611-622. doi: 10.1182/blood-2014-02-554980
    [17]
    TABACCO S, GIANNINI A, GARUFI C, et al. Complementemia in pregnancies with antiphospholipid syndrome[J]. Lupus, 2019, 28(13): 1503-1509. doi: 10.1177/0961203319882507
    [18]
    SALET D M, BEKKERING S, MIDDELDORP S, et al. Targeting thromboinflammation in antiphospholipid syndrome[J]. J Thromb Haemost, 2023, 21(4): 744-757. doi: 10.1016/j.jtha.2022.12.002
    [19]
    COLE M A, GERBER G F, CHATURVEDI S. Complement biomarkers in the antiphospholipid syndrome: approaches to quantification and implications for clinical management[J]. Clin Immunol, 2023, 257: 109828. DOI: 10.1016/j.clim.2023.109828.
    [20]
    SAUTER R J, SAUTER M, REIS E S, et al. Functional relevance of the anaphylatoxin receptor C3aR for platelet function and arterial thrombus formation marks an intersection point between innate immunity and thrombosis[J]. Circulation, 2018, 138(16): 1720-1735. doi: 10.1161/CIRCULATIONAHA.118.034600
    [21]
    MEZGER M, NORDING H, SAUTER R, et al. Platelets and immune responses during thromboinflammation[J]. Front Immunol, 2019, 10: 1731. DOI: 10.3389/fimmu.2019.01731.
    [22]
    SUBRAMANIAM S, JURK K, HOBOHM L, et al. Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development[J]. Blood, 2017, 129(16): 2291-2302. doi: 10.1182/blood-2016-11-749879
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (43) PDF downloads(2) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return